IRIS
SCIONTI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.495
AS - Asia 1.092
EU - Europa 816
SA - Sud America 175
AF - Africa 56
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.644
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.421
SG - Singapore 450
IT - Italia 390
CN - Cina 194
IN - India 129
BR - Brasile 128
GB - Regno Unito 101
DE - Germania 99
VN - Vietnam 89
FI - Finlandia 52
CA - Canada 44
HK - Hong Kong 44
SE - Svezia 34
NL - Olanda 30
PK - Pakistan 27
JO - Giordania 24
ID - Indonesia 22
BD - Bangladesh 21
MX - Messico 21
ES - Italia 17
FR - Francia 16
RU - Federazione Russa 16
ZA - Sudafrica 15
CZ - Repubblica Ceca 12
EG - Egitto 12
IQ - Iraq 12
CO - Colombia 11
TR - Turchia 11
SA - Arabia Saudita 10
LT - Lituania 8
NG - Nigeria 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
AR - Argentina 7
IR - Iran 7
PT - Portogallo 7
VE - Venezuela 7
AU - Australia 6
ET - Etiopia 6
KE - Kenya 6
LB - Libano 6
RO - Romania 6
EC - Ecuador 5
IE - Irlanda 5
MA - Marocco 5
MY - Malesia 5
AL - Albania 4
CY - Cipro 4
JP - Giappone 4
PH - Filippine 4
UA - Ucraina 4
BG - Bulgaria 3
CL - Cile 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
KR - Corea 3
PS - Palestinian Territory 3
PY - Paraguay 3
TH - Thailandia 3
UZ - Uzbekistan 3
AT - Austria 2
AZ - Azerbaigian 2
CH - Svizzera 2
EU - Europa 2
IL - Israele 2
KZ - Kazakistan 2
LK - Sri Lanka 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BO - Bolivia 1
CD - Congo 1
CM - Camerun 1
EE - Estonia 1
GE - Georgia 1
HU - Ungheria 1
JM - Giamaica 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.644
Salva come PNG Salva come JPEG
Città #
San Jose 266
Singapore 209
Ashburn 166
Chandler 161
Dallas 89
Munich 72
Santa Clara 71
Bengaluru 57
Hefei 57
Chicago 55
London 50
Ho Chi Minh City 40
Milan 39
Beijing 38
Turku 35
Hong Kong 34
Lawrence 34
Princeton 34
Catanzaro 32
Los Angeles 22
Boardman 19
Ottawa 19
Helsinki 17
Amman 16
Hanoi 16
New York 15
Wilmington 15
Rome 13
São Paulo 13
Carbonia 12
San Nicola Manfredi 12
Atlanta 10
Chennai 10
San Francisco 10
Spezzano della Sila 10
The Dalles 10
Brooklyn 9
Madrid 9
Delhi 8
Irbid 8
Manchester 8
Montreal 8
Naples 8
Olomouc 8
Palermo 8
Catania 7
Cosenza 7
Da Nang 7
Kaunas 7
Bari 6
Des Moines 6
Ercolano 6
Frankfurt am Main 6
Hyderabad 6
Nairobi 6
Redmond 6
Seattle 6
Addis Ababa 5
Afragola 5
Ahmedabad 5
Aversa 5
Bologna 5
Cardiff 5
Council Bluffs 5
Dhaka 5
Islamabad 5
Jeddah 5
Johannesburg 5
Lahore 5
Lucknow 5
Meppel 5
Mexico City 5
Orem 5
Pune 5
Riyadh 5
Sacramento 5
Santo Stefano di Rogliano 5
Stockholm 5
Ankara 4
Brescia 4
Cape Town 4
Charlotte 4
Florianópolis 4
Haiphong 4
Istanbul 4
Kuala Lumpur 4
Lima 4
Melbourne 4
Nicosia 4
Paris 4
Phoenix 4
Tanta 4
Toronto 4
Tubarão 4
Acquaviva delle Fonti 3
Ajman 3
Amsterdam 3
Andover 3
Baghdad 3
Banyumas 3
Totale 2.115
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 452
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 138
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
miR-22 suppresses DNA ligase III addiction in multiple myeloma 102
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 93
A 46,XY Female with a 9p24.3p24.1 Deletion and a 8q24.11q24.3 Duplication: A Case Report and Review of the Literature. 81
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 78
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 78
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 74
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 73
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 71
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 70
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 68
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 66
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 65
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 61
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 60
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 59
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 59
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 58
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 57
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization 56
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 56
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 56
The Cytoscan HD Array in the Diagnosis of Neurodevelopmental Disorders 53
GENETIC SUSCEPTIBILITY TO GASTROINTESTINAL SYMPTOMS IN FABRY DISEASE 51
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 51
Integration of DNA Microarray with Clinical and Genomic Data 51
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 51
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 50
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 50
Mmrf-commpass data integration and analysis for identifying prognostic markers 50
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 48
Exploring the impact of lipid droplets on the evolution and progress of hepatocarcinoma 47
DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine 47
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 46
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 46
Ethical Perspectives on Pharmacogenomic Profiling 45
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 44
The Effect of Physical Activity/Exercise on miRNA Expression and Function in Non-Communicable Diseases-A Systematic Review 44
null 43
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. (IF 5.168) 39
Advances in Alport syndrome diagnosis using next-generation sequencing 36
The potential role of miRNAs in multiple myeloma therapy 34
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 34
Raman spectroscopic characterization of liver steatosis and fibrosis in a 2D and 3D in vitro thyroxine-treated hypothyroid cellular model 31
null 31
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 30
GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma 29
Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications 28
High frequency of COH1 intragenic deletions and duplications detected by MLPA in patients with Cohen syndrome 25
Clinical Implementation of Sustainable Functional Foods and Nutraceuticals in Metabolic Health: A Feasibility Study 22
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 13
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 9
Totale 3.777
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.949
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 12 1 0
2021/2022156 1 0 0 32 8 0 8 29 36 19 17 6
2022/2023453 75 31 22 19 59 40 7 33 60 33 49 25
2023/2024511 91 40 46 35 48 74 28 41 10 17 31 50
2024/2025976 92 33 33 50 62 126 73 60 56 23 156 212
2025/20261.559 130 173 147 191 168 95 250 91 195 119 0 0
Totale 3.777